Al­tim­mune shares slide as the FDA flash­es a red light for the IND work on their in­tranasal Covid-19 vac­cine

The FDA has or­dered Al­tim­mune $ALT to hit the brakes on their shift in­to the clin­ic with an in­tranasal Covid-19 vac­cine.

The biotech says that the agency has fair­ly be­nign in­ten­tions, main­tain­ing that reg­u­la­tors halt­ed the IND ap­pli­ca­tion so they could get cer­tain pro­to­col mod­i­fi­ca­tions and ad­di­tion­al CMC da­ta. This is, how­ev­er, the first time the agency has put up a red light for a vac­cine de­vel­op­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.